Thyroid Gland Carcinoma — Variants & evidence

Thyroid Gland Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

104 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 101–104 of 104 evidence items (3 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NTRK1 Fusion1
Larotrectinib	Thyroid Gland Papillary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID11747 FFPE samples from 351 primary thyroid carcinomas were subjected to targeted gene rearrangement next-generation sequencing, and 11 NTRK rearrangements were found, all with intact kinase domains, and in… (full text at CIViC) PMID 32457407 · Chu et al., 2020 · Open in CIViC	civic
TSC2 Q1178*1
Everolimus	Thyroid Gland Carcinoma	Predictive	C	Supports Sensitivity Response	5	accepted	EID1108 In a phase II trial of everolimus in thyroid cancer (NCT00936858), seven patients with anaplastic thyroid carcinoma were treated, and only one patient achieved an objective response. This 57-year-old … (full text at CIViC) PMID 25295501 · Wagle et al., 2014 · Open in CIViC	civic
ALK Fusion1
Crizotinib	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID5954 A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor … (full text at CIViC) PMID 24687827 · Godbert et al., 2015 · Open in CIViC	civic
RET Fusion1
Selpercatinib	Thyroid Gland Papillary CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID7069 In this phase 1 trial, patients with RET-fusion or mutation positive cancers were treated with the selective RET-inhibitor selpercatinib (LOXO-292). Among the 6 patients with RET-fusion positive papil… (full text at CIViC) Open in CIViC	civic

Data updated 13 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.